Gene Editing
STAT+: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43 billion.
The deal helps Pfizer, flush with cash but in need of new sources of revenue due to declining sales of Covid treatments, by adding a lineup of cancer drugs called antibody-drug conjugates that work by delivering chemotherapy directly to tumors.
